21917-88-4

Basic information

• Product Name: 6,7-DIHYDRO-5H-ISOQUINOLIN-8-ONE
• Synonyms: 6,7-DIHYDRO-5H-ISOQUINOLIN-8-ONE;6,7-DIHYDROISOQUINOLIN-8(5H)-ONE;8(5H)-isoquinolinone,6,7-dihydro-;6,7-Dihydro-5H-Isoquinolinon-8-one;5,6,7,8-tetrahydroisoquinoline-5,8-dione;6,7-dihydro-8(5H)-Isoquinolinone;6,7-dihydroisoquinolin-8(5H)-one hydrochloride;6,7- two-5H- hydrogenisoquinoline-8- ketone
• CAS NO: 21917-88-4
• Molecular Formula: C₉H₉NO
• Molecular Weight: 147.17
• Product Categories: Isoquinoline Derivertives
• Mol File: 21917-88-4.mol

Chemical Properties

• Melting Point: 42-44 °C
• Boiling Point: 266.169 °C at 760 mmHg
• Flash Point: 121.849 °C
• Appearance: /
• Density: 1.168 g/cm³
• Vapor Pressure: 0.009mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• PKA: 3.80±0.20(Predicted)
• CAS DataBase Reference: 6,7-DIHYDRO-5H-ISOQUINOLIN-8-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-DIHYDRO-5H-ISOQUINOLIN-8-ONE(21917-88-4)
• EPA Substance Registry System: 6,7-DIHYDRO-5H-ISOQUINOLIN-8-ONE(21917-88-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 21917-88-4(Hazardous Substances Data)

Usage

Uses

Used in Catalyst Preparation:
6,7-Dihydro-5H-isoquinolin-8-one is used as a catalyst in the study of the origins of catalysis in nornicotine aqueous aldol reactions. Its unique chemical structure allows it to facilitate and enhance the reaction process, making it a valuable component in the field of catalysis.
Used in Pharmaceutical Industry:
6,7-Dihydro-5H-isoquinolin-8-one is used as an intermediate in the synthesis of various pharmaceutical compounds. Its versatile chemical structure enables it to be a key component in the development of new drugs, particularly those targeting the central nervous system.
Used in Chemical Research:
6,7-DIHYDRO-5H-ISOQUINOLIN-8-ONE is also utilized in chemical research as a model system for studying the properties and reactivity of isoquinolinone derivatives. Its unique structure provides insights into the behavior of similar compounds and contributes to the advancement of chemical knowledge.

InChI:InChI=1/C9H9NO/c11-9-3-1-2-7-4-5-10-6-8(7)9/h4-6H,1-3H2

Upstream product

• 36556-06-6 5,6,7,8-tetrahydroisoquinoline 
• 7664-93-9 sulfuric acid 
• 64-19-7 acetic acid 
• 22971-46-6 5-oxo-5-(pyridin-3-yl)pentanoic acid 
• 87549-96-0 1-(pyridin-3-yl)cyclobutanol 
• 151330-02-8 methyl 6,7-dihydro-8(5H)-isoquinolinone-7-carboxylate 

Downstream Products

• 101584-53-6 8-(4-methoxy-benzyl)-5,6,7,8-tetrahydro-isoquinolin-8-ol 
• 855268-64-3 8-benzyl-5,6,7,8-tetrahydro-isoquinolin-8-ol 
• 139484-36-9 7,8-epoxy-7,8-dihydroisoquinoline 
• 139484-34-7 7,8-epoxy-5,6,7,8-tetrahydroisoquinoline 
• 36556-06-6 5,6,7,8-tetrahydroisoquinoline 
• 1338952-25-2 (E,Z)-8-(2-(3-Chlorophenyl)hydrazono)-5,6,7,8-tetrahydroisoquinoline 
• 132725-67-8 8-benzyl-5,6,7,8-tetrahydro-isoquinoline 
• 113454-04-9 8-benzylidene-5,6,7,8-tetrahydro-isoquinoline 
• 1213648-37-3 5,6,7,8-tetrahydroisoquinolin-8-amine 
• 139484-32-5 5,6,7,8-tetrahydroisoquinolin-8-ol 

Relevant articles and documents

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

Decarboxylative Intramolecular Arene Alkylation Using N-(Acyloxy)phthalimides, an Organic Photocatalyst, and Visible Light

An intramolecular arene alkylation reaction has been developed using the organic photocatalyst 4CzIPN, visible light, and N-(acyloxy)phthalimides as radical precursors. Reaction conditions were optimized via high-throughput experimentation, and electron-rich and electron-deficient arenes and heteroarenes are viable reaction substrates. This reaction enables access to a diverse set of fused, partially saturated cores which are of high interest in synthetic and medicinal chemistry.

Mercaptan compound having HDAC6 (histone deacetylase 6) inhibitory activity and application thereof

The invention belongs to the technical field of medicines and relates to a mercaptan compound having an anti-tumor activity, in particular to a mercaptan compound containing a 6(7)-substituted-N-(6-decylhexyl)-pyrazolo[3,4-e] indazole-3-formamide fragment

a, ? UNSATURATED AMIDE COMPOUND

The present invention provides an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

Tandem Oxidative Ring-Opening/Cyclization Reaction in Seconds in Open Atmosphere for the Synthesis of 1-Tetralones in Water-Acetonitrile

A mild and practical tandem oxidative ring-opening/cyclization reaction mediated by Ce4+ for the synthesis of 1-tetralones is presented. This rapid transformation was completed within 30 s and conducted in an open reactor at 0 °C in a water-acetonitrile mixture. Various cyclobutanol derivatives are transformed into desired products in good to high yields, and this reaction can be easily scaled up to the gram scale.

Tandem Oxidative Ring-Opening/Cyclization Reaction in Seconds in Open Atmosphere for the Synthesis of 1-Tetralones in Water-Acetonitrile

A mild and practical tandem oxidative ring-opening/cyclization reaction mediated by Ce4+ for the synthesis of 1-tetralones is presented. This rapid transformation was completed within 30 s and conducted in an open reactor at 0 °C in a water-acetonitrile mixture. Various cyclobutanol derivatives are transformed into desired products in good to high yields, and this reaction can be easily scaled up to the gram scale.

Synthesis and Antiproliferative Activity of Some Ellipticine-Like 11H-Pyrido[a]carbazole Derivatives

Some modified 11H-pyrido[a]carbazoles (11H-PyC) and their corresponding tetrahydro derivatives (11H-THPyC) were prepared. A common multistep pathway characterized by conventional reactions, including a Fischer-indole-type synthesis, yielded the tetracycli

Synthesis of 3h-quinazolin-4-ones and 4h-3,1-benzoxazin-4-ones via benzylic oxidation and oxidative dehydrogenation using potassium iodide-tert-butyl hydroperoxide

A simple and elegant method for benzylic activation was demonstrated employing the potassium iodide/tert-butyl hydrogen peroxide catalytic system. This methodology was further extended for the synthesis of biologically important heterocycles namely, 3H-quinazolin-4-ones and 4H-3,1-benzoxazin-4-ones including mecloqualone and etaqualone which are important quinazolinone-based drugs used for the treatment of insomnia in good yields.

(±)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents

Several amine-substituted 8-amino-5,6,7,8-tetrahydroisoquinolines were examined as conformationally-constrained analogs of the nicotinic cholinergic (nACh) 3-(aminomethyl)pyridines. Although these ligands failed to bind at nACh receptors, the N-ethyl-N-methyl analog 3d was found to be at least equipotent with nicotine in rodent tests of antinociception. The mechanism of action of 3d is currently unknown.

Synthesis, optical resolution, absolute configuration, and preliminary pharmacology of (+)- and (-)-cis-2,3,3a,4,5,9b-hexahydro-1-methyl-1H-pyrrolo- [3,2-h]isoquinoline, a structural analog of nicotine

Title compound, 8, has been synthesized from isoquinolinone, 1 (an improved preparation for which is presented) and separated into its antipodes with D- and L-di-p-toluoyltartaric acids. These antipodes and the racemic precursor have been evaluated (and found active) in two in vivo systems for their effects. The most potent of the three, (+)-8, has an ED50 of 7.13 μmol/kg for inhibition of spontaneous activity and 7.45 μmol/kg for antinociception compared to 4.44 and 4.81 μmol/kg, respectively, for (S)-(- )-nicotine. Compounds (-)-8 and 7 are about one-fourth as potent. Isomer (+)- 8 has the 3aR,9bS configuration, the latter corresponding to (S)-(-)-nicotine as determined by X-ray crystallography. However, (+)-8 failed to compete for [3H]-nicotine binding, and its pharmacological effects were not blocked by mecamylamine. These bridged nicotine analogs either are binding to an as- yet-unidentified nicotinic receptor or they represent a novel class of non- nicotinic analgesics.